Exhibit 99.1
Capricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate Update
Planning to Initiate HOPE-2 Clinical Trial
To Host Conference Call and Webcast Today at 4:30 p.m. ET
LOS ANGELES, March 14, 2018 – Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today reported its fourth quarter and full year 2017 financial results. It also provided a corporate update.
“This has been an exciting year for Capricor as we have made significant inroads in the clinical development of CAP-1002, our lead cell therapy product, to treat Duchenne muscular dystrophy,” said Linda Marbán, Ph.D., Capricor president and chief executive officer. “We have achieved several important milestones that facilitate our progress in the research, development and potential commercialization of CAP-1002. We will soon be initiating the HOPE-2 clinical trial designed to test CAP-1002 in boys and young men whose ability to walk has been impaired by Duchenne muscular dystrophy. This trial is one of the very few to focus on those patients that are non-ambulant and in the later stages of the disease process.”
Fourth Quarter Highlights and Recent Clinical and Operational Developments
| · | In November, Capricor reported the one-year results of its first clinical trial of CAP-1002, the HOPE-Duchenne trial, at the American Heart Association Scientific Sessions 2017. The study found that a single intracoronary dose of CAP-1002 produced significant and sustained improvement in cardiac and skeletal muscle functions in boys and young men in advanced stages of Duchenne muscular dystrophy, a serious x-linked genetic disorder for which there is no cure and treatment options are limited. |
| · | The Food and Drug Administration (FDA) cleared Capricor’s Investigational New Drug (IND) application to conduct the HOPE-2 trial which is a randomized, double-blind, placebo-controlled study in later stage Duchenne muscular dystrophy patients. |
| · | A newly published study in “Stem Cell Reports” from the Smidt Heart Institute at Cedars-Sinai Medical Center reported that CAP-1002 improved skeletal, diaphragm and cardiac muscle function in a mouse model of Duchenne muscular dystrophy. |
| · | Capricor secured two additional FDA designations that may potentially expedite reviews and regulatory approval of CAP-1002 for Duchenne muscular dystrophy: the Regenerative Medicine Advanced Therapy (RMAT) designation, which makes therapies eligible for expedited review, and the Rare Pediatric Disease Designation, which means that if CAP-1002 is approved first for use in Duchenne muscular dystrophy, the company may secure a priority review voucher to fast-track a potential future therapy. These two designations are in addition to the Orphan Drug Designation Capricor secured in February 2017. |
| · | Capricor added seven new patent applications to its existing Exclusive License Agreements with Cedars-Sinai Medical Center, giving Capricor worldwide, exclusive rights to inventions related to cardiosphere-derived cells (CDCs, CAP-1002) and CDC-derived extracellular vesicles, including exosomes. |
| · | Capricor hosted a Key Opinion Leaders Lunch in New York City on March 9 which included four distinguished speakers discussing the emerging paradigms in gene and cellular therapies to treat Duchenne muscular dystrophy. The speakers included Craig McDonald, M.D., professor and chair of the Department of Physical Medicine and Rehabilitation and Director of the Neuromuscular Disease Clinics at the University of California, Davis. He is the national principal investigator of the Capricor HOPE-2 trial. Other speakers were Jeffrey Chamberlain, Ph.D., professor in the departments of Neurology, Medicine and Biochemistry and director of the Seattle Wellstone Muscular Dystrophy Center, and Michelle Eagle, Ph.D., the managing director of ATOM International LTD and one of the creators of, and who has published extensively on, the Performance of the Upper Limb (PUL) test, a validated test for skeletal muscle function in Duchenne muscular dystrophy. PUL is the primary efficacy endpoint for the HOPE-2 trial. The fourth speaker was Pat Furlong, the founding president and CEO of the Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the U.S. focused solely on Duchenne. |
Anticipated Events and Milestones in 2018
| · | Plan to treat the first patients in the HOPE-2 clinical trial. |
| · | Continue to conduct pre-clinical research for Capricor’s investigational exosome-based therapy, CAP-2003, to treat various diseases of inflammation and fibrosis, including hypoplastic left heart syndrome. |
| · | Continue preparations for manufacturing scale-up and technology transfer of CAP-1002. |
Fourth Quarter and Full Year Financial Results
For the fourth quarter of 2017, after giving effect to the forgiveness of the California Institute of Regenerative Medicine (CIRM) loan payable, the company reported net income of approximately $12.3 million, or $0.42 per diluted share, compared to a net loss of approximately $(4.5) million, or $(0.21) per diluted share, for the fourth quarter of 2016.
For the year ended December 31, 2017, after giving effect to the forgiveness of the CIRM loan payable, the company reported net income of approximately $2.4 million, or $0.09 per diluted share, compared to a net loss of approximately $(18.8) million, or $(1.01) per diluted share for the year ended December 31, 2016. As of December 31, 2017, the company's cash, cash equivalents and marketable securities totaled approximately $14.1 million compared to approximately $16.2 million on December 31, 2016.
In the fourth quarter of 2017, the company notified CIRM of its election to abandon the ALLSTAR (CIRM-funded) project pursuant to the Loan Agreement and entered into an Amendment whereby the total loan balance was forgiven by CIRM, thereby terminating the company’s obligation to repay the loan balance. The company classified the forgiveness of the loan payable, a non-cash income, of approximately $15.7 million as “other income” in its Consolidated Statement of Operations.
Financial Outlook
Based on current plans and projections, Capricor expects that its cash, cash equivalents and marketable securities will fund its research and development programs and other operations through the fourth quarter of 2018.
Conference Call and Webcast
To participate in the conference call, please dial 866-717-4562 (U.S.) or 210-874-7812 (international) and enter the conference ID of 4139889. To join via webcast, please visit: https://edge.media-server.com/m6/p/gwkzzdrc. The webcast will be archived for approximately 30 days.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. The HOPE-Duchenne trial was funded in part by CIRM. For more information, visit www.capricor.com.
Keep up with Capricor on social media: www.facebook.com/capricortherapeutics, www.instagram.com/capricortherapeutics/ and https://twitter.com/capricor
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the Securities and Exchange Commission on March 16, 2017, in its Registration Statement on Form S-3, as filed with the Securities and Exchange Commission on September 28, 2015, together with the prospectus included therein and prospectus supplements thereto, and in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 14, 2017. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
CAP-1002 is an Investigational New Drug and is not approved for any indications. CAP-2003 has not yet been approved for clinical investigation.
CAPRICOR THEAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(unaudited)
| Three months ended December 31 | Years ended December 31 | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| INCOME | ||||||||||||||||
| Collaboration income | $ | - | $ | 683,595 | $ | 1,367,186 | $ | 3,190,106 | ||||||||
| Grant income | 344,575 | 223,335 | 1,115,430 | 808,512 | ||||||||||||
| Other income | 131,224 | - | 183,724 | - | ||||||||||||
| TOTAL INCOME | 475,799 | 906,930 | 2,666,340 | 3,998,618 | ||||||||||||
| OPERATING EXPENSES | ||||||||||||||||
| Research and development | 2,518,395 | 2,665,904 | 10,766,095 | 16,042,082 | ||||||||||||
| General and administrative | 1,237,827 | 1,154,355 | 4,762,642 | 4,933,054 | ||||||||||||
| TOTAL OPERATING EXPENSES | 3,756,222 | 3,820,259 | 15,528,737 | 20,975,136 | ||||||||||||
| LOSS FROM OPERATIONS | (3,280,423 | ) | (2,913,329 | ) | (12,862,397 | ) | (16,976,518 | ) | ||||||||
| OTHER INCOME (EXPENSE) | ||||||||||||||||
| Investment income | 11,768 | (1,940 | ) | 38,494 | 14,407 | |||||||||||
| Interest expense | (80,307 | ) | (102,905 | ) | (398,807 | ) | (344,665 | ) | ||||||||
| Forgiveness of loan payable | 15,654,133 | - | 15,654,133 | - | ||||||||||||
| Impairment of in-process research and development | - | (1,500,000 | ) | - | (1,500,000 | ) | ||||||||||
| TOTAL OTHER INCOME (EXPENSE) | 15,585,594 | (1,604,845 | ) | 15,293,820 | (1,830,258 | ) | ||||||||||
| NET INCOME (LOSS) | 12,305,171 | (4,518,174 | ) | 2,431,423 | (18,806,776 | ) | ||||||||||
| OTHER COMPREHENSIVE INCOME (LOSS) | ||||||||||||||||
| Net unrealized gain (loss) on marketable securities | 3,027 | 2,601 | 8,096 | (5,861 | ) | |||||||||||
| COMPREHENSIVE INCOME (LOSS) | $ | 12,308,198 | $ | (4,515,573 | ) | $ | 2,439,519 | $ | (18,812,637 | ) | ||||||
| Net income (loss) per share - basic | $ | 0.48 | $ | (0.21 | ) | $ | 0.10 | $ | (1.01 | ) | ||||||
| Weighted average number of shares - basic | 25,810,249 | 21,399,019 | 23,193,278 | 18,551,013 | ||||||||||||
| Net income (loss) per share - diluted | $ | 0.42 | $ | (0.21 | ) | $ | 0.09 | $ | (1.01 | ) | ||||||
| Weighted average number of shares - diluted | 29,471,009 | 21,399,019 | 26,788,076 | 18,551,013 | ||||||||||||
CAPRICOR THEAPEUTICS, INC.
SUMMARY BALANCE SHEETS
| December 31, 2017 | December 31, 2016 | |||||||
| Cash, cash equivalents and marketable securities | $ | 14,124,935 | $ | 16,194,888 | ||||
| Total assets | $ | 16,273,789 | $ | 18,747,355 | ||||
| Total deferred revenue | - | 1,367,186 | ||||||
| Total liabilities | $ | 5,046,934 | $ | 22,750,509 | ||||
| Total stockholders' equity (deficit) - 26,270,491 and 21,399,019 common shares issued and outstanding at December 31, 2017 and December 31, 2016, respectively | 11,226,855 | (4,003,154 | ) | |||||
| Total liabilities and stockholders' equity | $ | 16,273,789 | $ | 18,747,355 | ||||
For more information, please contact:
AJ Bergmann, Chief Financial Officer
+1-310-358-3200
abergmann@capricor.com